Jeil Pharma Holdings Valuation
Is A002620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A002620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A002620 (₩10560) is trading above our estimate of fair value (₩479.26)
Significantly Below Fair Value: A002620 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A002620?
Other financial metrics that can be useful for relative valuation.
What is A002620's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩162.11b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.5x |
Enterprise Value/EBITDA | 11.9x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A002620's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x | ||
A214390 Kyongbo Pharmaceutical | 0.8x | n/a | ₩177.9b |
A002390 HANDOK | 0.4x | n/a | ₩190.3b |
A011040 Kyung Dong Pharmaceutical | 1.1x | n/a | ₩172.8b |
A023910 Daihan PharmaceuticalLtd | 0.9x | 8.6% | ₩167.3b |
A002620 Jeil Pharma Holdings | 0.2x | n/a | ₩162.1b |
Price-To-Sales vs Peers: A002620 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does A002620's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Sales vs Industry: A002620 is good value based on its Price-To-Sales Ratio (0.2x) compared to the KR Pharmaceuticals industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is A002620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A002620's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.